NEW YORK, April 29, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Insys Therapeutics, Inc. (NASDAQ: INSY), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Lannett Company, Inc. (NYSE: LCI) and Magellan Health Services Inc. (NASDAQ: MGLN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1741-100free.
AMAG Pharmaceuticals, Inc. Analyst Notes
On April 24, 2014, AMAG Pharmaceuticals, Inc. (AMAG) reported its Q1 2014 financial results. Quarterly total revenues increased 16.5% YoY to $20.8 million while net loss came in at $7.1 million, or diluted loss of $0.33, compared with $3.9 million or diluted loss of $0.18 per share in Q1 2013. William Heiden, President and CEO attributed the strong revenue growth to the outstanding execution of the business plan, especially with the outstanding sales performance of its Feraheme and MuGard, which captured a large portion of market share from other IV iron products. "In addition to operating the business effectively and with continued financial discipline this quarter, AMAG completed a $200 million convertible debt offering in February, which will enhance our ability to complete business development transactions to expand our product portfolio," Heiden added. The full analyst notes on AMAG are available to download free of charge at:
Insys Therapeutics, Inc. Analyst Notes
On April 22, 2014, Insys Therapeutics, Inc. (Insys Therapeutics) announced that the Company will present at the 39th Annual Deutsche Bank Health Care Conference on May 7, 2014 and May 8, 2014 at the InterContinental Hotel in Boston, M.A. Michael L. Babich, President and CEO, and Darryl Baker, CFO, will host the presentation on May 8, 2015 at 2:50 p.m. EDT. A live audio webcast, as well as its replay, will be made available on the Company's website for 30 days after the initial presentation. The full analyst notes on Insys Therapeutics are available to download free of charge at:
WuXi PharmaTech (Cayman) Inc. Analyst Notes
On April 22, 2014, WuXi PharmaTech (Cayman) Inc. announced that it will release its Q1 2014 financial results on May 14, 2014, after the close of the New York Stock Exchange. The Company's senior management will host a conference call on May 15, 2014, at 8:00 a.m. US ET (5:00 a.m. US PT, 8:00 p.m. Beijing, Shanghai, Hong Kong). The conference call, as well as the telephone replay, will be made available after the call's completion at the Investor Relations section of the Company's website. The full analyst notes on Cayman are available to download free of charge at:
Lannett Company, Inc. Analyst Notes
On April 15, 2014, Lannett Company, Inc. (Lannett Company) announced that it has received approval from US FDA of its Abbreviated New Drug Application (ANDA) for Diazepam Oral Solution (Concentrate) 5mg/mL, believed to be the first bioequivalent Diazepam Oral Solution product approved by the FDA. Diazepam is therapeutically equivalent to reference listed drugs, Diazepam Intensol Oral Solution (Concentrate), 5mg/mL of Roxane Laboratories, Inc. Arthur P. Bedrosian, President and CEO of Lanett said that the Company continuously develop and file applications for controlled substances. At present, a total of 16 product applications are still pending at FDA and another 55 products are in various stages of development. The full analyst notes on Lannett are available to download free of charge at:
Magellan Health Services Inc. Analyst Notes
On April 24, 2014, Magellan Health Services Inc. (Magellan Health Services) announced that members of its executive team will be presenting at two upcoming conferences. CFO Jonathan N. Rubin will present at the Deutsche Bank 39th Annual Health Care Conference on May 7, 2014, at 9:20 a.m. ET at the InterContinental Hotel in Boston, while Chairman and CEO Barry M. Smith will present at the Bank of American Merrill Lynch 2014 Health Care Conference on May 14, 2014 at 1:00 p.m. PT (4:00 p.m. ET) at the Encore at the Wynn in Las Vegas. The conference audio and presentation materials will be made available on the Company's website. The full analyst notes on Magellan Health Services are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review